OncLive TV

Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the future of treatments for patients with renal cell carcinoma (RCC).

Mark D. Pegram, MD, director of the Breast Cancer Oncology Program at Stanford Medicine, discusses pertuzumab (Perjeta) plus trastuzumab (Herceptin) and chemotherapy for patients with HER2-positive breast cancer.

Loretta J. Nastoupil, MD, Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses an early-phase trial looking at the triplet regimen of TGR1202, ublituximab, and ibrutinib (Imbruvica) in patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL).

Dana M. Chase, MD, FACOG, an associate professor at Creighton University, University of Arizona College of Medicine, and gynecologic oncologist with Arizona Oncology, discusses the future treatment landscape of gynecologic malignancies, including vulvar cancer, endometrial cancer, and cervical cancer.

Peter Black, MD, senior research scientist, Vancouver Prostate Centre, associate professor, Department of Urologic Sciences, University of British Columbia, discusses biomarker development in bladder cancer.

Henry M. Kuerer, MD, PhD, professor of surgery, The University of Texas MD Anderson Cancer Center, discusses margins of ductal carcinoma in situ (DCIS).

Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the next steps with sipuleucel-T (Provenge) for patients with prostate cancer.

Andrew J. Stephenson, MD, director for the Center of Urologic Oncology at the Cleveland Clinic, discusses advancements being made in the field of prostate cancer.

Jihad Kaouk, MD, urologist, Cleveland Clinic, discusses challenges regarding robotic surgery for patients with renal cell carcinoma (RCC).

Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses developments of immunotherapy trials for patients with head and neck cancer.

Hans-Joachim Schmoll, MD, head, Department of Oncology and Hematology, associate professor, Internal Medicine, Hematology/ Oncology, University Hospital Halle, discusses the objective of the CHARTA study for patients with colorectal cancer (CRC).

Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses microsatellite instability testing in patients with gynecologic malignancies.

Anne Chiang, MD, PhD, professor and thoracic oncologist at Yale Cancer Center, discusses ipilimumab (Yervoy) plus nivolumab (Opdivo) in small cell lung cancer.

John C. Byrd, MD, D. Warren Brown Chair of Leukemia Research, professor of Medicine, Medicinal Chemistry and Veterinary Biosciences, director, Division of Hematology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, discusses the updated findings of the RESONATE trial in chronic lymphocytic leukemia (CLL).

Paul A. Hamlin, MD, of Memorial Sloan Kettering Cancer Center, discusses the toxicities reported in a phase I dose-escalation study of buparlisib plus ibrutinib (Imbruvica) in patients with mantle cell lymphoma (MCL), follicular lymphoma (FL), and diffuse large B-cell lymphoma (DLBCL).

Joel Neal, MD, an assistant professor of medicine and oncology at Stanford Medicine, discusses whether, if approved by the FDA, alectinib (Alecensa) will become the frontline standard of care for patients with ALK-positive non–small cell lung cancer (NSCLC).

Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of surgery, Harvard Medical School, discusses managing patients with prostate cancer under active surveillance.

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses challenges with immunotherapy in head and neck cancer.

Kenneth H. Shain, MD, PhD, assistant member, Moffitt Cancer Center, discusses the impact of subcutaneous therapy, such as bortezomib (Velcade) and daratumumab (Darzalex) for patients with multiple myeloma.

Peter Martin, MD, assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the toxicities related to stem cell transplantation for patients with mantle cell lymphoma (MCL).

Costas Lallas, MD, professor at Sidney Kimmel Medical College, Thomas Jefferson University Hospital, discusses ongoing trials investigating immunotherapy regimens for patients with genitourinary malignancies.

Simon Chowdhury, PhD, MA, MBBS, MRCP, consultant medical oncologist specializing in urological cancer, Sarah Cannon Research Institute, United Kingdom, discusses sequencing of immunotherapy regimens for patients with renal cell carcinoma (RCC).

Peter Black, MD, senior research scientist, Vancouver Prostate Centre, associate professor, Department of Urologic Sciences, University of British Columbia, discusses immunotherapy biomarkers in bladder cancer.

Shilpa Gupta, MD, assistant professor, Hematology Oncology and Transplantation Division, University of Minnesota, discusses adjuvant immunotherapy in kidney cancer.

Barbara Burtness, MD, professor of medicine, Yale Cancer Center, discusses challenges regarding immunotherapy for patients with head and neck cancer.

Toni K. Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses trials investigating combinations for patients with renal cell carcinoma (RCC).

John P. Leonard, MD, professor of Medicine at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses some of the exciting advancements taking place in the field of mantle cell lymphoma (MCL).

Seungtaek L. Choi, MD, an assistant professor in the Department of Radiation Oncology, and clinical Medical Director, Department of Genitourinary Medical Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, discusses the considering factors for patients to receive radiation therapy (RT) for their prostate cancer.

Ruben Niesvizky, MD, professor of medicine, Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medical College/NewYork-Presbyterian Hospital, discusses sequencing agents for patients with multiple myeloma.

Gail Roboz, MD, a professor of Medicine and director of the Clinical and Translational Leukemia Program at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the challenges clinicians are facing with chimeric antigen receptor (CAR) T-cell therapy in acute lymphoblastic leukemia (ALL).